Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to estimate the prevalence of HPV infections anal and ENT level and according to HIV status in transgender (TG) population. The main question it aims to answer is: - What is the prevalence of HPV lesions in transgender population (TG); - What kind of high risk HPV (hrHPV) and low risk HPV (lrHPV) are detected at the genital, anal and ENT level


Clinical Trial Description

Context: The few publications with an individualized transgender (TG) population have been conducted in South America (Peru, Argentina) showing very high anal or ano-genital hrHPV prevalences of around 97% (dos Ramos Farias et al., 2011; Brown et al., 2016). Recently a study conducted in 22 TGs showed a high prevalence of anal dysplastic lesions with low grade lesions detected in 8 individuals and high grade in 3 individuals (Kobayashi et al., 2017). Thus, in the face of this high prevalence of 50% anal dysplasia, the TG population therefore appears to be at risk for developing anal dysplastic lesions and this needs to be explored in another TG population. Furthermore, to our knowledge, no study has evaluated the concomitant prevalence of hrHPV infection at the anogenital and ENT levels in the transgender population. The Infectious and Tropical Diseases Department of Bichat-Claude Bernard Hospital is particularly involved in the follow-up of transgender individuals with a large active file that participates in clinical research projects (Pommier et al., 2019; Bertin et al., 2019; Phung et al., 2018). Objectives: Principal objective The primary objective of this study is to determine the prevalence of HPV lesions in transgender population (TG). Secondary objectives Secondary objectives include: 1. Estimate the prevalence of HPV infections at the genital, anal and ENT level and according to HIV status; 2. To estimate the prevalence of hrHPV infections at the genital, anal and ENT levels, globally and according to HIV status; 3. To estimate the prevalence of lrHPV infections at the genital, anal and ENT level globally and by HIV status; 4. Describe the types of hrHPV and lrHPV detected at the genital, anal and ENT level; 5. To estimate the prevalence of dysplastic lesions (low grade and high grade) by HIV status; 6. To estimate the prevalence of bacterial Sexually Transmitted Infections (STIs): Neisseria gonorrhoeae, Chlamydia trachomatis and Syphilis, globally and by anatomical site and HIV status. Methodology This is a national, non-interventional, cross-sectional, monocentric study among TG people (man to woman, and woman to man) Estimated enrolment 200 participants Outcomes Primary outcome: The prevalence of HPV infections among TG people. Prevalence is defined as the percentage of subjects with HPV infection among TG people included, regardless the site where infection was detected. Secondary outcomes: 1. The prevalence of HPV infections in each anatomical site (genital, anal and ENT) and by HIV status. 2. The prevalence of hrHPV infections in each anatomical site (genital, anal and ENT), globally and according to HIV status. 3. The prevalence of lrHPV infections in each anatomical site (genital, anal and ENT), globally and by HIV status. 4. The types of hrHPV and lrHPV in each anatomical site (genital, anal). 5. The prevalence of dysplastic lesions (low grade and high grade) by HIV status. 6. The prevalence of bacterial STIs: Neisseria gonorrhoeae, Chlamydia trachomatis and Syphilis, globally, by anatomical site and HIV status. Eligibility Inclusion criteria - Age ≥ 18 years - To belong to transgender population : i.e. people who doesn't identify to the gender assigned at birth - To be affiliated to a social security system or be beneficiary of the Aide Médicale d'Etat (AME) Non-inclusion criteria - To have ever been vaccinated against HPV - Research participation refusal - People under guardianship or curatorship, or deprived of liberty by administrative or judiciary measure Statistical methods Individuals' characteristics will be described for all included subjects. Continuous variables will be described using mean, standard deviation, median, interquartiles values, minimal and maximal values. Qualitative variables will be described using numbers and percentages by modality. Prevalences will be described by proportion and their confidence interval will be calculated under binomial law. All statistical tests will be performed using 5% as significance level. Prevalence of high risk HPV infection in each anatomical site and the concordance of HPV types by anatomical site will be determined using Fleiss Kappa test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05981807
Study type Observational
Source ANRS, Emerging Infectious Diseases
Contact Jade GHOSN, MD PhD
Phone (+33) 1 40 25 78 03
Email jade.ghosn@aphp.fr
Status Not yet recruiting
Phase
Start date October 2023
Completion date October 2024

See also
  Status Clinical Trial Phase
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Recruiting NCT05889689 - Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters N/A
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Completed NCT03063385 - Puerto Rico Cuidalos Parent-adolescent Program N/A
Completed NCT02009046 - Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students N/A
Completed NCT01411878 - Louisville Teen Pregnancy Prevention Project N/A
Completed NCT01303575 - Internet-Based Sexual Health Education for Middle School Native American Youth N/A
Completed NCT00167505 - All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students N/A
Completed NCT00183456 - A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs Phase 2
Completed NCT00336180 - Adolescent Drug and HIV Prevention in South Africa Phase 2/Phase 3
Completed NCT00161382 - Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students N/A
Completed NCT01084395 - Reducing HIV Risk Among Mexican Youth N/A
Completed NCT00710060 - Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations Phase 3
Completed NCT00640653 - Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents N/A
Completed NCT00289939 - Reducing HIV & Domestic Violence Risk in Women Offenders Phase 3
Completed NCT00137943 - Parents Matter!: Interventions to Promote Effective Parent-Child Communication Phase 1
Completed NCT03408743 - Engineering an Online STI Prevention Program: CSE2 N/A
Completed NCT06104813 - Evaluation of Deaf Men's Knowledge About Sexual Health
Not yet recruiting NCT05910580 - Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years N/A